Financials
Financial year 2025
Revenue
€ 81.8 million
▲ 9% vs 2024
Profit
Growing€ 2.2 million
▲ 33% vs 2024
Debts
Normal€ 26.7 million
▲ 31% vs 2024
Teva Pharma Belgium from Antwerpen, company number BE0451951110, closed financial year 2025 with a result of € 2.2 million after tax. For that financial year Teva Pharma Belgium recorded revenue of € 81.8 million and equity of € 6.7 million. Compared with financial year 2024, the result moved from € 1.6 million to € 2.2 million. Profitable, and profit is growing. The buffer is growing. Debts are under control. The most recent annual accounts were filed with the National Bank of Belgium on June 2, 2026.
What happened at Teva Pharma Belgium?
What happened at Teva Pharma Belgium in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- Ines Marinovic stepped down as director. NBB
- Michiel Letteboer stepped down as director. NBB
- Jan Willem Scheer stepped down as director. NBB
- New annual accounts for financial year 2025: profit of € 2.2 million (▲ 33% vs 2024). Source: NBB ↗
- Michiel Letteboer became a director. NBB
- Jan Willem Scheer became a director. NBB
- Ines Marinovic became a director. NBB
- New establishment in Antwerpen. KBO
In short
From € 987,105 profit in 2021 to € 2.2 million profit in 2025.
Paid € 2.7 million in corporate taxes since 2021.
Best year ever: 2025, with € 2.2 million profit.
Paid out € 16 million in dividends to the owners in total.
A new publication or filing at Teva Pharma Belgium? We notify you, reason included.
Follow Teva Pharma BelgiumNeed more data?
History
Every financial year, as far back as the National Bank goes.
Buffer
How long does the company survive without income?
Credit limit
Indicative credit limit, computed from the real figures.
Alerts
News about who you follow, reason included.
Then €29.99/mo excl. VAT, cancel monthly. No credit card to try; the AI assistant is not included, or only in a very limited form, during the trial month. Sign up now and you’ll be invited first.
Management
Directors
According to the 2025 annual accounts
Ines Marinovic
Director
since 2023 · until 2028
Michiel Letteboer
Director
since 2025 · until 2028
Jan Willem Scheer
Director
since 2025 · until 2028
Establishments
Establishment units
Physical locations of this company
Sneeuwbeslaan 20 box 20
2610 Antwerpen
Laarstraat 16 A
2610 Antwerpen
Active since 21 March 1994
Laarstraat 16
2610 Antwerpen
Active since 1 January 2016
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 41 companies are registered at this address.
Association belge des Analystes financiers - Belgische Vereniging der Financiële Analisten
€ -15,281 gross margin · 2025
ETION Synergia
€ -1.1 million gross margin · 2025
Mediwe
€ 3.3 million revenue · 2025
MCS
€ 4.9 million revenue · 2025
BURGER BRANDS BELGIUM
€ 51.1 million revenue · 2021
+36 more
Details
- Company number
- 0451.951.110
- VAT number
- BE 0451.951.110
- Registered office
- Sneeuwbeslaan 20 bus 20, 2610 Antwerpen
- Names & denominations
- Teva Pharma Belgium · Teva
- Enterprise type
- Rechtspersoon
- Legal form
- Public limited company
- Legal situation
- Normale toestand
- Start date
- 3 February 1994
- Peppol
- Active · Active since 8 Dec 2025
- Activities · NACE
Groothandel in farmaceutische producten
Groothandel in farmaceutische en medische artikelen
Activiteiten van adviesbureaus op het gebied van bedrijfsvoering en overig managementadvies
Groothandel in chemische producten voor industrieel gebruik
Vervaardiging van medische en tandheelkundige instrumenten en benodigdheden
Vervaardiging van niet-elektrische apparaten en instrumenten voor de geneeskunde, de tandheelkunde en de veeartsenijkunde
Overige adviesbureaus op het gebied van bedrijfsvoering en beheer
Groothandel in chemische producten
+1